Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 295

1.

Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer.

Albitar M, Sudarsanam S, Ma W, Jiang S, Chen W, Funari V, Blocker F, Agersborg S.

Oncotarget. 2018 Feb 8;9(17):13682-13693. doi: 10.18632/oncotarget.24455. eCollection 2018 Mar 2.

2.

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.

Agersborg S, Mixon C, Nguyen T, Aithal S, Sudarsanam S, Blocker F, Weiss L, Gasparini R, Jiang S, Chen W, Hess G, Albitar M.

Breast Cancer Res Treat. 2018 Jul;170(2):321-328. doi: 10.1007/s10549-018-4755-5. Epub 2018 Mar 22.

PMID:
29564742
3.

Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.

Albitar M, Ma W, Lund L, Shahbaba B, Uchio E, Feddersen S, Moylan D, Wojno K, Shore N.

Prostate. 2018 Mar;78(4):294-299. doi: 10.1002/pros.23473. Epub 2018 Jan 8.

PMID:
29315679
4.

A Multi-Center Prospective Study to Validate an Algorithm Using Urine and Plasma Biomarkers for Predicting Gleason ≥3+4 Prostate Cancer on Biopsy.

Albitar M, Ma W, Lund L, Shahbaba B, Uchio E, Feddersen S, Moylan D, Wojno K, Shore N.

J Cancer. 2017 Aug 2;8(13):2554-2560. doi: 10.7150/jca.20031. eCollection 2017.

5.

Prevalence of somatic mutations in patients with aplastic anemia using peripheral blood cfDNA as compared with BM.

Albitar A, Townsley D, Ma W, De Dios I, Funari V, Young NS, Albitar M.

Leukemia. 2018 Jan;32(1):227-229. doi: 10.1038/leu.2017.271. Epub 2017 Aug 23. No abstract available.

6.

Acquired RhD mosaicism identifies fibrotic transformation of thrombopoietin receptor-mutated essential thrombocythemia.

Montemayor-Garcia C, Coward R, Albitar M, Udani R, Jain P, Koklanaris E, Battiwalla M, Keel S, Klein HG, Barrett AJ, Ito S.

Transfusion. 2017 Sep;57(9):2136-2139. doi: 10.1111/trf.14201. Epub 2017 Jun 26.

PMID:
28653329
7.

Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.

Ma W, Brodie S, Agersborg S, Funari VA, Albitar M.

Mol Diagn Ther. 2017 Oct;21(5):571-579. doi: 10.1007/s40291-017-0290-z.

8.
9.

Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.

Albitar A, Ma W, DeDios I, Estella J, Ahn I, Farooqui M, Wiestner A, Albitar M.

Oncotarget. 2017 Mar 14;8(11):17936-17944. doi: 10.18632/oncotarget.15316.

10.

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, Stetler-Stevenson M, Soto S, Valdez J, Nierman P, Lotter J, Xi L, Raffeld M, Farooqui M, Albitar M, Wiestner A.

Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.

11.

Prevalence and relative proportions of CLL and non-CLL monoclonal B-cell lymphocytosis phenotypes in the Middle Eastern population.

Aljurf M, Rawas F, Alnounou R, Bakshi N, Chaudhri N, Khalil S, Almohareb F, Albitar M.

Hematol Oncol Stem Cell Ther. 2017 Mar;10(1):42-43. doi: 10.1016/j.hemonc.2016.09.003. Epub 2016 Nov 9. No abstract available.

12.

Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).

Berman E, Jhanwar S, Hedvat C, Arcila ME, Wahab OA, Levine R, Maloy M, Ma W, Albitar M.

Leuk Res. 2016 Oct;49:108-12. doi: 10.1016/j.leukres.2016.08.006. Epub 2016 Aug 12.

13.

Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome.

Albitar F, Ma W, Diep K, De Dios I, Agersborg S, Thangavelu M, Brodie S, Albitar M.

Genet Test Mol Biomarkers. 2016 Jul;20(7):341-5. doi: 10.1089/gtmb.2015.0278. Epub 2016 Jun 1.

PMID:
27248906
14.

Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic Malignancies.

Aljurf M, Abalkhail H, Alseraihy A, Mohamed SY, Ayas M, Alsharif F, Alzahrani H, Al-Jefri A, Aldawsari G, Al-Ahmari A, Belgaumi AF, Walter CU, El-Solh H, Rasheed W, Albitar M.

Biotechnol Res Int. 2016;2016:8589270. doi: 10.1155/2016/8589270. Epub 2016 Feb 23.

15.

Predicting Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring System.

Albitar M, Ma W, Lund L, Albitar F, Diep K, Fritsche HA, Shore N.

J Cancer. 2016 Feb 2;7(3):297-303. doi: 10.7150/jca.12771. eCollection 2016.

16.

Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acid.

Albitar A, Ma W, DeDios I, Estella J, Agersborg S, Albitar M.

Int J Lab Hematol. 2016 Apr;38(2):133-40. doi: 10.1111/ijlh.12456. Epub 2016 Jan 21.

PMID:
26797804
17.

Synonymous Polymorphisms in HOXB13 as a Protective Factor for Prostate Cancer.

Albitar F, Diep K, Ma W, Albitar M.

J Cancer. 2015 Feb 27;6(5):409-11. doi: 10.7150/jca.11413. eCollection 2015.

18.

Dysregulation of ubiquitin-proteasome pathway and apolipoprotein A metabolism in sickle cell disease-related pulmonary arterial hypertension.

Anjum F, Lazar J, Soh J, Albitar M, Gowda S, Hussain MM, Wadgaonkar R.

Pulm Circ. 2013 Dec;3(4):851-5. doi: 10.1086/674763.

19.

Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.

Ma W, Diep K, Fritsche HA, Shore N, Albitar M.

Genet Test Mol Biomarkers. 2014 Mar;18(3):156-63. doi: 10.1089/gtmb.2013.0424. Epub 2014 Feb 10.

PMID:
24512523
20.

Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.

Akard LP, Cortes JE, Albitar M, Goldberg SL, Warsi G, Wetzler M, Ericson SG, Radich JP.

Arch Pathol Lab Med. 2014 Sep;138(9):1186-92. doi: 10.5858/arpa.2013-0584-OA. Epub 2013 Dec 5.

PMID:
24308645
21.

Company Profile: NeoGenomics Laboratories, Inc.

Albitar M, Bacharach A.

Per Med. 2012 Nov;9(8):795-799. doi: 10.2217/pme.12.98.

PMID:
29776233
22.

The t(9;11) confers good prognosis in AML patients treated with stem cell transplantation as compared to non-t(9;11) and other adverse-risk abnormalities.

Walter CU, Mohareb FA, Chaudhri N, Alsharif F, Zahrani HA, Mohamed S, Rasheed W, Saleh AJ, Chebbo W, El Gohary G, Aljurf M, Albitar M.

Hematol Oncol Stem Cell Ther. 2012;5(3):169-70. doi: 10.5144/1658-3876.2012.169. No abstract available.

23.

Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.

Minagar A, Ma W, Zhang X, Wang X, Zhang K, Alexander JS, Gonzalez-Toledo E, Albitar M.

Neurol Res. 2012 Jul;34(6):611-8. doi: 10.1179/1743132812Y.0000000055. Epub 2012 Jun 16.

PMID:
22709658
24.

Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma.

Landgren O, Ma W, Kyle RA, Rajkumar SV, Korde N, Albitar M.

Leukemia. 2012 Apr;26(4):844-5. doi: 10.1038/leu.2011.262. Epub 2011 Sep 16. No abstract available.

PMID:
21926963
25.

Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling.

Lee TS, Kantarjian H, Ma W, Yeh CH, Giles F, Albitar M.

PLoS One. 2011;6(8):e23396. doi: 10.1371/journal.pone.0023396. Epub 2011 Aug 17.

26.

Trainable immunohistochemical HER2/neu image analysis: a multisite performance study using 260 breast tissue specimens.

Nassar A, Cohen C, Agersborg SS, Zhou W, Lynch KA, Albitar M, Barker EA, Vanderbilt BL, Thompson J, Heyman ER, Lange H, Olson A, Siddiqui MT.

Arch Pathol Lab Med. 2011 Jul;135(7):896-902. doi: 10.1043/2010-0418-OAR1.1.

PMID:
21732780
27.

Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.

Reicher S, Boyar FZ, Albitar M, Sulcova V, Agersborg S, Nga V, Zhou Y, Li G, Venegas R, French SW, Chung DS, Stabile BE, Eysselein VE, Anguiano A.

Pancreas. 2011 Oct;40(7):1057-62. doi: 10.1097/MPA.0b013e3182200201.

PMID:
21705950
28.

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.

Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M, Anderson KC.

Br J Haematol. 2011 Jun;153(6):729-40. doi: 10.1111/j.1365-2141.2011.08664.x. Epub 2011 Apr 28.

PMID:
21534941
29.

Reading immunohistochemical slides on a computer monitor--a multisite performance study using 180 HER2-stained breast carcinomas.

Nassar A, Cohen C, Albitar M, Agersborg SS, Zhou W, Lynch KA, Heyman ER, Lange H, Siddiqui MT.

Appl Immunohistochem Mol Morphol. 2011 May;19(3):212-7. doi: 10.1097/PAI.0b013e3181f5e84d.

PMID:
21475038
30.

Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease.

Qu KZ, Zhang K, Ma W, Li H, Wang X, Zhang X, Giles F, Lai M, Afdhal NH, Albitar M.

J Gastroenterol Hepatol. 2011 Apr;26(4):751-8. doi: 10.1111/j.1440-1746.2010.06491.x.

PMID:
21418304
31.

Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.

Sanders HR, Li HR, Bruey JM, Scheerle JA, Meloni-Ehrig AM, Kelly JC, Novick C, Albitar M.

Cancer Genet. 2011 Jan;204(1):45-52. doi: 10.1016/j.cancergencyto.2010.08.024.

PMID:
21356191
32.

MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.

Ma W, Zhang X, Wang X, Zhang Z, Yeh CH, Uyeji J, Albitar M.

Diagn Mol Pathol. 2011 Mar;20(1):34-9. doi: 10.1097/PDM.0b013e3181ecd261.

PMID:
21326037
33.

Circulating microRNAs as biomarkers for hepatocellular carcinoma.

Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M.

J Clin Gastroenterol. 2011 Apr;45(4):355-60. doi: 10.1097/MCG.0b013e3181f18ac2.

PMID:
21278583
34.

Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors.

Ma W, Giles F, Zhang X, Wang X, Zhang Z, Lee TS, Yeh CH, Albitar M.

Int J Lab Hematol. 2011 Jun;33(3):326-31. doi: 10.1111/j.1751-553X.2010.01291.x. Epub 2011 Jan 26.

PMID:
21266020
35.

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA.

Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. Review.

36.

Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.

Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, Donahue AC, Zhang Z, Yeh CH, O'Brien S, Garcia-Manero G, Caporaso N, Landgren O, Albitar M.

BMC Med Genet. 2010 Nov 16;11:163. doi: 10.1186/1471-2350-11-163.

37.

Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.

Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, Albitar M.

Leuk Res. 2011 Apr;35(4):526-33. doi: 10.1016/j.leukres.2010.09.009. Epub 2010 Oct 15.

38.

Somatic mutations of signaling genes in non-small-cell lung cancer.

Sanders HR, Albitar M.

Cancer Genet Cytogenet. 2010 Nov;203(1):7-15. doi: 10.1016/j.cancergencyto.2010.07.134. Review.

PMID:
20951313
39.

Long-term follow-up of monoclonal B-cell lymphocytosis detected in environmental health studies.

Marti GE, Shim YK, Albitar M, Middleton D, Abbasi F, Anderson A, Vogt RF.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S83-90. doi: 10.1002/cyto.b.20522.

40.

JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.

Ma W, Kantarjian H, Zhang X, Wang X, Zhang Z, Yeh CH, O'Brien S, Giles F, Bruey JM, Albitar M.

PLoS One. 2010 Aug 13;5(8):e12165. doi: 10.1371/journal.pone.0012165.

41.

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M, Anderson KC.

Br J Haematol. 2010 Aug;150(4):428-37. doi: 10.1111/j.1365-2141.2010.08264.x. Epub 2010 Jul 7.

42.

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.

Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, Mitsiades CS, Anderson KC.

Br J Haematol. 2010 Aug;150(4):438-45. doi: 10.1111/j.1365-2141.2010.08265.x. Epub 2010 Jul 7. Erratum in: Br J Haematol. 2010 Sep;150(6):731.

43.

Quantification of intracellular proteins and monitoring therapy using flow cytometry.

Chang RL, Yeh CH, Albitar M.

Curr Drug Targets. 2010 Aug;11(8):994-9. Review.

PMID:
20426764
44.

Circulating CD33 and its clinical value in acute leukemia.

Abdool A, Yeh CH, Kantarjian H, O'Brien S, Bruey J, Giles F, Albitar M.

Exp Hematol. 2010 Jun;38(6):462-71. doi: 10.1016/j.exphem.2010.03.016. Epub 2010 Apr 1.

PMID:
20362641
45.

Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia.

Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, Sanders H, O'Brien S, Keating M, Albitar M.

Leuk Res. 2010 Oct;34(10):1320-4. doi: 10.1016/j.leukres.2010.03.010. Epub 2010 Apr 1.

46.

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.

Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR.

Leukemia. 2010 Apr;24(4):699-705. doi: 10.1038/leu.2009.292. Epub 2010 Jan 28.

PMID:
20111068
47.

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.

Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ.

J Clin Oncol. 2010 Feb 10;28(5):815-21. doi: 10.1200/JCO.2009.24.2008. Epub 2009 Dec 21.

PMID:
20026800
48.

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG.

Br J Haematol. 2010 Feb;148(3):386-93. doi: 10.1111/j.1365-2141.2009.07965.x. Epub 2009 Nov 6.

49.

Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.

Tsai HT, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB, Marti GE, Albitar M, Ghia P, Rajkumar SV, Landgren O.

Blood. 2009 Dec 3;114(24):4928-32. doi: 10.1182/blood-2009-08-237651. Epub 2009 Oct 14.

50.

Clinical correlation of circulating heat shock protein 70 in acute leukemia.

Yeh CH, Tseng R, Hannah A, Estrov Z, Estey E, Kantarjian H, Albitar M.

Leuk Res. 2010 May;34(5):605-9. doi: 10.1016/j.leukres.2009.09.014. Epub 2009 Oct 1.

Supplemental Content

Loading ...
Support Center